Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2009 - 2017)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash from Restructuring of -$2.1 million for Q4 2017, down 392.97% year-over-year from $725000.0 in Q4 2016, and up 24.28% quarter-over-quarter from -$2.8 million in Q3 2017.
Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2009 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Cash from Restructuring history runs 9 years deep, the most recent figure standing at -$2.1 million for Q4 2017.
- In Q4 2017, Cash from Restructuring fell 392.97% year-over-year to -$2.1 million; the TTM figure through Dec 2017 stood at -$6.0 million (up 19.38% YoY), while the FY2017 annual figure was -$6.0 million, up 19.38% from the prior year.
- Cash from Restructuring for Q4 2017 stood at -$2.1 million, up from -$2.8 million in the prior quarter.
- The five-year high for Cash from Restructuring was $36.6 million in Q3 2014, with the low at -$24.4 million in Q1 2015.
- The 5-year median for Cash from Restructuring is -$1.6 million (2015), against an average of -$1.1 million.
- Peak annual rise in Cash from Restructuring reached 796.18% in 2014, while the deepest fall reached 1099.75% in 2014.
- Vertex Pharmaceuticals' Cash from Restructuring stood at $2.2 million in 2013, then plunged by 540.05% to -$9.7 million in 2014, then surged by 74.96% to -$2.4 million in 2015, then surged by 129.7% to $725000.0 in 2016, then tumbled by 392.97% to -$2.1 million in 2017.
- Business Quant data shows VRTX's Cash from Restructuring at -$2.1 million in Q4 2017, -$2.8 million in Q3 2017, and -$1.4 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -2.12 Mn |
| Sep 30, 2017 | -2.81 Mn |
| Jun 30, 2017 | -1.36 Mn |
| Mar 31, 2017 | 305,000.00 |
| Dec 31, 2016 | 725,000.00 |
| Sep 30, 2016 | -5.26 Mn |
| Jun 30, 2016 | -1.43 Mn |
| Mar 31, 2016 | -1.46 Mn |
| Dec 31, 2015 | -2.44 Mn |
| Sep 30, 2015 | -2.04 Mn |
| Jun 30, 2015 | -1.65 Mn |
| Mar 31, 2015 | -24.37 Mn |
| Dec 31, 2014 | -9.75 Mn |
| Sep 30, 2014 | 36.62 Mn |
| Jun 30, 2014 | -4.88 Mn |
| Mar 31, 2014 | -4.49 Mn |
| Dec 31, 2013 | 2.22 Mn |
| Sep 30, 2013 | 4.09 Mn |
| Jun 30, 2013 | -407,000.00 |
| Mar 31, 2013 | -869,000.00 |